Allan J.W. Lui

Also affiliated with Kettering University, Cancer Research UK Cambridge Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions”.

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3321

N/A

1.9DataRank · unranked

48 citations

Adam J. Schoenfeld, Evan Siau, Yue Christine Lu, Huichun Tai, Ken Suzawa +17 more

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Cancer Discovery(2022)10.1158/2159-8290.cd-21-1119

N/A

0.770DataRank · unranked

169 citations

Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J. Sisso, Marissa S. Mattar +17 more

The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3605

N/A

0.593DataRank · unranked

51 citations

Allan J.W. Lui, Whitney J. Sisso, Eric Gladstone, Zebing Liu, Lukas Delasos +10 more

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Nature Cancer(2023)10.1038/s43018-023-00630-y

N/A

0.553DataRank · unranked

39 citations

Igor Odintsov, Keiji Ishida, Allan J.W. Lui, Masanori Kato, Tatsuya Suzuki +28 more

Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.03.013

N/A

0.524DataRank · unranked

32 citations

Marissa S. Mattar, Allan J.W. Lui, Michael Offin, Christopher Kurzatkowski, Lukas Delasos +9 more

Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.2024

N/A

0.330DataRank · unranked

8 citations

Allan J.W. Lui, Kota Ishizawa, Isao Miyazaki, Inna Khodos, Kentaro Wakayama +11 more

CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma

Cancer Research(2022)10.1158/0008-5472.can-21-1397

N/A

0.292DataRank · unranked

6 citations

Michael V. Ortiz, Inna Khodos, Marissa S. Mattar, Allan J.W. Lui, Shinji Kohsaka +5 more

Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling

Disease Models & Mechanisms(2021)10.1242/dmm.047621

N/A

0DataRank · unranked

33 citations

Igor Odintsov, Zebing Liu, Allan J.W. Lui, Takuo Hayashi, Morana Vojnic +22 more

Data from CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma

(2023)10.1158/0008-5472.c.6513894.v1

N/A

0DataRank · unranked

0 citations

Michael V. Ortiz, Inna Khodos, Marissa S. Mattar, Allan J.W. Lui, Shinji Kohsaka +5 more

HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1835

N/A

0DataRank · unranked

19 citations

Christopher A. Febres‐Aldana, Zebing Liu, Jenna-Marie Dix, Ryan Cheng, Raymond G. Dematteo +13 more